The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women - Wikidata - awgldk - TriplyDB

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

http://www.wikidata.org/entity/Q29396434

about

Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis European guidance for the diagnosis and management of osteoporosis in postmenopausal women Venous thromboembolic disease Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta Tamoxifen: catalyst for the change to targeted therapy Osteoporosis and its management Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system.Breast cancer prevention A new day dawns: women without oestrogen or is a balance best?Endogenous hormones and the aetiology of breast cancer.Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer.Hormonal control of p53 and chemoprevention Future possibilities in the prevention of breast cancer: breast cancer prevention trials.Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention.Oestrogen exposure and breast cancer risk Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.Selective Estrogen Receptor Modulators New insights into treatment of osteoporosis in postmenopausal women Molecular cancer prevention: Current status and future directions The evolution of selective estrogen receptor modulators in osteoporosis therapy The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective Main controversies in breast cancer The 2.0 Å crystal structure of the ERα ligand-binding domain complexed with lasofoxifene Breast cancer chemoprevention: progress and controversy.Breast cancer chemoprevention: old and new approaches The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil Medical prevention of breast cancer Familiar drugs may prevent cancer Profile of V. Craig Jordan Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells Rheumatology: 15. Osteoporosis Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer

P2860

Q24200755-96F9B12A-A00E-459C-A98C-CDF149F0C36A Q24612411-24690C84-80A4-4E8E-985A-72A4A3FA0031 Q24631121-86AB50AB-A7AE-4237-88EC-250377052455 Q24632806-C4714C39-E9FC-4D5E-840D-1C0BEFA5CF2E Q24652988-E923E2F6-089D-4F79-ADF9-270A70AED458 Q24670075-A413BB47-3CE7-4068-9D37-59B6E83DCBB1 Q24670339-17893C8F-8FBB-4C80-8838-8B534433A1C5 Q24791032-5D6D1544-ECA5-447E-9AB4-D45ECF93292D Q24797803-26A08CEF-5951-4ECE-85B8-FDE7F7677E47 Q24800226-2224AFF7-9033-47D4-86BC-C9CF8199F6C8 Q24800587-FC54906D-279F-4EA7-B2AC-CE9921190CA0 Q24800731-78B6A1EC-F4C2-4427-839F-6A471C7D9B4D Q24802454-643E75A4-4EC2-43A3-A3B8-906996275D27 Q24803259-27C2C982-523D-4001-95A7-69BDB62D6237 Q24803306-0BCE9F7C-0FFE-4B90-B3A6-8735C2DA6055 Q24803327-3FE8EE26-39C2-4A4E-AFC8-9738231D730D Q24803498-A181C3E0-306A-4EA6-82F9-8B573A18B1AC Q24803990-03B346C8-A361-4278-BF90-05C954D87C5E Q24806501-C47696C6-FE38-42BF-9897-767F1A7D98AB Q24810287-B0BF2E13-E988-4041-B5EC-803DBFE288FA Q25257858-7C4E3A8E-E531-497F-BB17-81124E8E106E Q26738923-6B10BA1D-B5C3-4968-9061-FE7352CF60A7 Q26777910-DCB2F5A2-EC80-4FC4-9DD1-4B9CA3544070 Q26797207-92948C93-B58E-495B-833E-CC3578048167 Q26827973-A06A2DC0-FD8F-4EF2-A4D1-85D38D20BC33 Q26830744-E3FE43D2-02F4-4109-8FD3-C35562586D53 Q26864207-6A908A3B-3549-4A90-9833-EA63247743CB Q27026673-B13E3AC2-66BA-40F2-89CB-94546AA557FD Q27644597-04CE387C-2629-42CB-8C1C-9BD122AA53CE Q27692587-941AA4D6-B197-420D-811B-34CA2FE45BE9 Q27693259-1CE0D121-DBD7-4545-A413-307174232C6D Q28080673-C3E1DA0E-805E-4205-B34A-F32A8DD0FF49 Q28086915-66B99BDD-EBDF-45F8-B6F5-95CA63E8F19E Q28186835-78BB3313-9378-43C9-B7B9-363DB274AB47 Q28253151-B4AA258A-7E77-4586-8522-C6B72F113E9B Q28343780-183C4CA0-FDED-42F8-BBA0-B92A5F7646E6 Q28343990-D2BB3843-0BCD-4903-8D8C-C10802A73A3F Q28344803-3560EDFE-A2D0-4A60-8640-BDB0353A0232 Q28365306-9084A556-1F9A-44F6-AD3B-79D1C9FC4279 Q28366565-493F9C70-E902-4D0E-8951-0E66DEA08BEE

P2860

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

http://www.wikidata.org/entity/Q29396434

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@ast

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@en

type

label

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@ast

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@en

prefLabel

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@ast

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@en

P1433

Q29396434-F5023D9A-96DF-4B81-B9F3-0FEA75713DC0

P1476

Q29396434-CAA0B654-72BC-4494-92D0-D2B97A6D7807

P2093

Q29396434-005133D2-3892-4577-AB99-887AA6F88827

Q29396434-36F068CD-185E-4348-B9AA-540DB645E07D

Q29396434-3F8A7913-FF08-492C-91E0-E5F5E961C0C6

Q29396434-4D7C8CCA-3723-4061-95FC-8302C1C3D597

Q29396434-817609DA-CC57-46C1-9F75-86C1253F53C4

Q29396434-9534A94B-D043-4757-A628-75B1C9D8D8D9

Q29396434-9991599B-7BAF-4BB7-A998-0ED8E85E0837

Q29396434-B4AF11CE-DD38-441C-9877-7FD67A61C5C9

Q29396434-CBE32C59-2020-47CD-8835-6AEE82905A16

Q29396434-CDB1BDE2-5DC8-4E45-80A9-7CA7359EA43E

P304

Q29396434-94695D3C-AE8D-41F1-830C-519C069B957E

P31

Q29396434-44078B72-BA23-45DC-8567-0E67C29F6C60

P3181

Q29396434-E956EE33-AC89-4B72-B853-48FD2192BBC2

P356

Q29396434-5E575AFD-8765-46FD-A7E0-FAB6239982A4

P407

Q29396434-CAF840A2-7EF2-46BE-BEA3-7B4230F2DE5A

P433

Q29396434-6B1B7331-98DD-44DB-83EF-88A5ED9A1DC5

P478

Q29396434-AA3EFB42-17AF-4353-A2DF-624D36461273

P50

Q29396434-03C4408C-B8DB-4B8A-B811-958EE9038544

Q29396434-3F7B03D5-FFEE-4392-8238-E698541A50D2

Q29396434-B13DC9F8-8896-4B4E-AC45-C41E4EB1FDE2

P577

Q29396434-B862AA5C-3B5E-4EE4-BAB1-6915CC8BC1DD

P5875

Q29396434-A31F0694-1AFD-4A18-9BA4-38E35D45211A

P698

Q29396434-053E97F4-DCEC-4C59-8980-53A8F9AE66AB

P3181

P356

JAMA.281.23.2189

P1433

Journal of the American Medical Association

P1476

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

@en

P2093

Alberto Costa

http://www.w3.org/2001/XMLSchema#string

Deborah Grady

http://www.w3.org/2001/XMLSchema#string

Dennis Black

http://www.w3.org/2001/XMLSchema#string

Joan E. Glusman

http://www.w3.org/2001/XMLSchema#string

Kathryn A. Krueger

http://www.w3.org/2001/XMLSchema#string

Marc E. Lippman

http://www.w3.org/2001/XMLSchema#string

Nina H. Bjarnason

http://www.w3.org/2001/XMLSchema#string

Stephen Eckert

http://www.w3.org/2001/XMLSchema#string

Steven R. Cummings

http://www.w3.org/2001/XMLSchema#string

Thomas Nickelsen

http://www.w3.org/2001/XMLSchema#string

P304

2189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2477651

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.281.23.2189

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

281

http://www.w3.org/2001/XMLSchema#string

P50

P577

1999-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236298518

http://www.w3.org/2001/XMLSchema#string

P698

10376571

http://www.w3.org/2001/XMLSchema#string